Thrombosis and cancer

Nature Reviews Clinical Oncology

Volumn 9, Issue 8, 2012, Pages 437-449

  Young, Annie ^a   Chapman, Oliver ^b   Connor, Carole ^c   Poole, Christopher ^a   Rose, Peter ^c   Kakkar, Ajay K ^d  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

^c SOUTH WARWICKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; APIXABAN; BEVACIZUMAB; CERTOPARIN; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERYTHROPOIETIN; FONDAPARINUX; HEPARIN; LENALIDOMIDE; LEPTIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; RIVAROXABAN; SELECTIN; SEMULOPARIN; TAMOXIFEN; THALIDOMIDE; THROMBOPLASTIN; WARFARIN;

AMBULATORY CARE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CARCINOGENESIS; CATHETER THROMBOSIS; CAUSE OF DEATH; CENTRAL VENOUS CATHETER; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; COMPRESSION THERAPY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE COURSE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYMPTOM; THROMBOGENESIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; HUMANS; NEOPLASMS; RISK FACTORS; THROMBOSIS;

EID: 84864436154     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.106     Document Type: Review

References (148)

1. White, R. H. et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch. Intern. Med. 165, 1782-1787 (2005). (Pubitemid 41138968)
2. Trousseau, A. in Clinique Medicale de l'Hotel-Dieu de Paris [French] 281-332 2nd edn (J.-B. Baillière et Fils, Paris, 1865).
3. House of Commons Health Committee. The Prevention of Venous Thromboembolism in Hospitalised Patients [online], http://www.publications. parliament.uk/pa/cm200405/cmselect/cmhealth/99/99.pdf (2005).
4. Lyman, G. H. & Khorana, A. A. Cancer, clots and consensus: New understanding of an old problem. J. Clin. Oncol. 27, 4821-4826 (2009).
5. Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M. & Lyman, G. H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110, 2339-2346 (2007). (Pubitemid 350100757)
6. Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M. & Lyman, G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 5, 632-634 (2007). (Pubitemid 46680709)
7. Heit, J. A. et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch. Intern. Med. 160, 809-815 (2000). (Pubitemid 30165241)
8. Blom, J. W., Doggen, C. J., Osanto, S. & Rosendaal, F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293, 715-722 (2005). (Pubitemid 40216041)
9. Levitan, N. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78, 285-291 (1999). (Pubitemid 29439263)
10. Stein, P. D. et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am. J. Med. 119, 60-68 (2006). (Pubitemid 43117468)
11. Khorana, A. A. et al. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol. 24, 484-490 (2006). (Pubitemid 46630468)
12. Khorana, A. A. & Connolly, G. C. Assessing risk of venous thromboembolism in the patient with cancer. J. Clin. Oncol. 27, 4839-4847 (2009).
13. Sallah, S., Wan, J. Y. & Nguyen, N. P. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb. Haemost. 87, 575-579 (2002). (Pubitemid 34302943)
14. Prandoni, P. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 327, 1128-1133 (1992).
15. Heit, J. A. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch. Intern. Med. 162, 1245-1248 (2002). (Pubitemid 34595030)
16. Rondina, M. T. et al. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thromb. Res. 129, 22-27 (2012).
17. Bluff, J. E., Brown, N. J., Reed, M. W. R. & Staton, C. A. Tissue factor, angiogenesis and tumour progression. Breast Cancer Res. 10, 204 (2008).
18. Winter, P. C. The pathogenesis of venous thromboembolism in cancer: Emerging links with tumour biology. Hematol. Oncol. 24, 126-133 (2006). (Pubitemid 44483905)
19. Petralia, G. A., Lemoine, N. R. & Kakkar, A. K. Mechanisms of disease: The impact of antithrombotic therapy in cancer patients. Nat. Clin. Pract. Oncol. 2, 356-363 (2005). (Pubitemid 43118122)
20. Furie, B. & Furie, B. C. Mechanisms of thrombus formation. N. Engl. J. Med. 359, 938-949 (2008).
21. Rickles, F. R., Hair, G. A., Zeff, R. A., Lee, E. & Bona, R. D. Tissue factor expression in human leukocytes and tumor cells. Thromb. Haemost. 74, 391-395 (1995).
22. Kakkar, A. K., Lemoine, N. R., Scully, M. F., Tebbutt, S. & Williamson, R. C. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br. J. Surg. 82, 1101-1104 (1995).
23. White, R. H., Chew, H. & Wun, T. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: Who is at highest risk? Thromb. Res. 120 (Suppl. 2), 29-40 (2007).
24. Boccaccio, C. & Comoglio, P. M. Genetic link between cancer and thrombosis. J. Clin. Oncol. 27, 4827-4833 (2009).
25. Sutherland, D. E., Weitz, I. C. & Liebman, H. A. Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis, and treatment. Am. J. Hematol. 72, 43-52 (2003). (Pubitemid 36043750)
26. Falanga, A., Marchetti, M., Vignoli, A. & Balducci, D. Clotting mechanisms and cancer: Implications in thrombus formation and tumor progression. Clin. Adv. Hematol. Oncol. 1, 673-678 (2003).
27. Ruf, W., Disse, J., Carneiro-Lobo, T. C., Yokota, N. & Schaffner, F. Tissue factor and cell signalling in cancer progression and thrombosis. J. Thromb. Haemost. 9 (Suppl. 1), 306-315 (2011).
28. Kasthuri, R. S., Taubman, M. B. & Mackman, N. Role of tissue factor in cancer. J. Clin. Oncol. 27, 4834-4838 (2009).
29. Boccaccio, C. et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434, 396-400 (2005). (Pubitemid 40469184)
30. Morel, O. et al. Procoagulant microparticles: Disrupting the vascular homeostasis equation? Arterioscler. Thromb. Vasc. Biol. 26, 2594-2604 (2006).
31. Napoleone, E. et al. Leptin upregulates tissue factor expression in human breast cancer MCF-7 cells. Thromb. Res. 129, 641-647 (2011).
32. Lip, G. Y., Chin, B. S. & Blann, A. D. Cancer and the prothrombotic state. Lancet Oncol. 3, 27-34 (2002). (Pubitemid 34121143)
33. Khorana, A. A. Malignancy, thrombosis and Trousseau: The case for an eponym. J. Thromb. Haemost. 1, 2463-2465 (2003).
34. Kosmaczewska, A. et al. Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol. Oncol. Res. 18, 479-489 (2012).
35. Verso, M. et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern. Emerg. Med. 3, 117-122 (2008).
36. Walsh-McMonagle, D. & Green, D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer 80, 649-655 (1997). (Pubitemid 27339818)
37. Donald, I. & Hunt, B. Thromboprophylaxis for the prevention of hospital-Acquired venous thromboembolism [online], http://www.bgs.org.uk/index. php?option=com-content&view=article&id=1999:bpgthromporphylaxis& catid=12:goodpractice&Itemid=106;%20 (2012).
38. O'Connell, C. et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J. Thromb. Haemost. 9, 305-311 (2011).
39. Levine, M. N. et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J. Thromb. Haemost. 10, 807-814 (2012).
40. Kamba, T. & McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer. 96, 1788-1795 (2007). (Pubitemid 46912024)
41. Palumbo, A. et al. Prevention of thalidomide-And lenalidomide-Associated thrombosis in myeloma. Leukemia 22, 414-423 (2008). (Pubitemid 351255436)
42. Imberti, D. et al. Clinical characteristics and management of cancer-Associated acute venous thromboembolism: Findings from the MASTER Registry. Haematologica 93, 273-278 (2008). (Pubitemid 351397716)
43. Verso, M. & Agnelli, G. Venous thromboembolism associated with long-Term use of central venous catheters in cancer patients. J. Clin. Oncol. 21, 3665-3675 (2003). (Pubitemid 46594061)
44. Kuderer, N. M. et al. Venous thromboembolism represents a major risk factor for early all-cause mortality in patients receiving cancer chemotherapy [abstract]. J. Clin. Oncol. 26 (Suppl. 15), a9521 (2008).
45. Chew, H. K., Wun, T., Harvey, D., Zhou, H. & White, R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166, 458-464 (2006).
46. Chew, H. K., Wun, T., Harvey, D. J., Zhou, H. & White, R. H. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J. Clin. Oncol. 25, 70-76 (2007). (Pubitemid 350003053)
47. Elting, L. S. et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch. Intern. Med. 164, 1653-1661 (2004). (Pubitemid 39037944)
48. Bergqvist, D. et al. Venous thromboembolism and cancer. Curr. Probl. Surg. 44, 157-216 (2007). (Pubitemid 46554923)
49. Scarvelis, D. et al. Hospital mortality due to pulmonary embolism and an evaluation of the usefulness of preventative interventions. Thromb. Res. 125, 166-170 (2010).
50. Prandoni, P. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100, 3484-3488 (2002). (Pubitemid 35303914)
51. Cohen, A. T. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98, 756-764 (2007). (Pubitemid 47555066)
52. McNeil, K. & Dunning, J. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart 93, 1152-1158 (2007). (Pubitemid 47311004)
53. Ashrani, A. A. et al. Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: A nested case-control study. Vasc. Med. 15, 387-397 (2010).
54. Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H. & Francis, C. W. Development and validation of a predictive model for chemotherapy- Associated thrombosis. Blood 111, 4902-4907 (2008).
55. National Institute for Health and Clinical Excellence. Venous thromboembolism-reducing the risk (CG92) [online], http://guidance.nice.org.uk/ CG92 (2010).
56. Khorana, A. A., Francis, C. W., Culakova, E. & Lyman, G. H. Risk factors for chemotherapy-Associated venous thromboembolism in a prospective observational study. Cancer 104, 2822-2829 (2005). (Pubitemid 41798294)
57. Thodiyil, P. A. & Kakkar, A. K. Variation in relative risk of venous thromboembolism in different cancers. Thromb. Haemost. 87, 1076-1077 (2002). (Pubitemid 34624894)
58. Paneesha, S. et al. Frequency, demographics and risk (according to tumour type or site) of cancer-Associated thrombosis among patients seen at outpatient DVT clinics. Thromb. Haemost. 103, 338-343 (2010).
59. Petralia, G. et al. Venous thromboembolism and cancer. The PERCEIVE registry [abstract]. J. Thromb. Haemost. 5 (Suppl. 2), P-T-489 (2007).
60. Blom, J. W. et al. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: Results of a record linkage study. J. Thromb. Haemost. 4, 529-535 (2006).
61. Alcalay, A. et al. Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival. J. Clin. Oncol. 24, 1112-1118 (2006). (Pubitemid 46638808)
62. Rodriguez, A. O. et al. Venous thromboembolism in ovarian cancer. Gynecol. Oncol. 105, 784-790 (2007). (Pubitemid 46734211)
63. Khorana, A. A. et al. Venous thromboembolism prophylaxis and treatment in cancer: A consensus statement of major guidelines panels and call to action. J. Clin. Oncol. 27, 4919-4926 (2009).
64. Agnelli, G. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann. Surg. 243, 89-95 (2006). (Pubitemid 43054059)
65. Haddad, T. C. & Greeno, E. W. Chemotherapy-induced thrombosis. Thromb. Res. 118, 555-568 (2006). (Pubitemid 44414957)
66. Levine, M. N. et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N. Engl. J. Med. 318, 404-407 (1988). (Pubitemid 18044179)
67. Hernandez, R. K., Sørensen, H. T., Pedersen, L., Jacobsen, J. & Lash, T. L. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: A Danish population-based cohort study. Cancer 115, 4442-4449 (2009).
68. Pritchard, K. I. et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J. Clin. Oncol. 15, 2302-2311 (1997). (Pubitemid 27251132)
69. Cavo, M. et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89, 826-831 (2004). (Pubitemid 38981342)
70. Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P. R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431-436 (2006). (Pubitemid 46630462)
71. Zangari, M. et al. Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin. Lymphoma 4, 32-35 (2003). (Pubitemid 36826874)
72. Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X. & Wu, S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-Analysis. JAMA 300, 2277-2285 (2008).
73. Kuenen, B. C. et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J. Clin. Oncol. 21, 2192-2198 (2003). (Pubitemid 46606369)
74. Lyman, G. H. et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490-5505 (2007). (Pubitemid 350232226)
75. Sallah, S. et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin. Cancer Res. 10, 7238-7243 (2004). (Pubitemid 39487710)
76. Rose, P. et al. Risk factors for cancer-Associated venous thromboembolism in outpatient deep venous thrombosis clinics. Br. J. Haematol. 150, 640-641 (2010).
77. Connolly, G. C. & Khorana, A. A. Emerging risk stratification approaches to cancer-Associated thrombosis: Risk factors, biomarkers and a risk score. Thromb. Res. 125 (Suppl. 2), 1-7 (2010).
78. Simanek, R. et al. A high platelet count independently predicts venous thromboembolism in cancer patients [abstract]. J. Thromb. Haemost. 5 (Suppl. 2), P-T-497 (2007).
79. Manly, D. A. et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb. Res. 125, 511-512 (2010).
80. Paneesha, S. et al. High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes. Br. J. Haematol. 135, 85-90 (2006). (Pubitemid 44337667)
81. Ay, C. et al. Prediction of venous thromboembolism in cancer patients. Blood 116, 5377-5382 (2010).
82. Mandala, M. et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: The 'SENDO experience'. Ann. Oncol. 23, 1416-1421 (2012).
83. Kakkar, A. K. Prevention of venous thromboembolism in the cancer surgical patient. J. Clin. Oncol. 27, 4881-4884 (2009).
84. Gould, M. K. et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (Suppl. 2), 227-277 (2012).
85. Geerts, W. H. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (Suppl. 6), 381-453 (2008).
86. Agnelli, G. et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Oncol. 10, 943-949 (2009).
87. Riess, H. et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a4033 (2010).
88. Maraveyas, A. et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur. J. Cancer 48, 1283-1292 (2011).
89. Agnelli, G. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N. Engl. J. Med. 366, 601-609 (2012).
90. Oncologic Drugs Advisory Committee. NDA 203213, Semuloparin sodium, Sanofi-Aventis [online], http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm308561.pdf (2012).
91. Haas, S. K. et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin. Appl. Thromb. Hemost. 18, 159-165 (2012).
92. Perry, J. R. et al. PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma [abstract]. J. Clin. Oncol. 25 (Suppl. 18), a2011 (2007).
93. Samama, M. M. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N. Engl. J. Med. 341, 793-800 (1999). (Pubitemid 29420474)
94. Leizorovicz, A. et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110, 874-879 (2004). (Pubitemid 39096017)
95. Cohen, A. T. et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 332, 325-329 (2006).
96. Kakkar, A. K. et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N. Engl. J. Med. 365, 2463-2472 (2011).
97. Kahn, S. R. et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (Suppl. 2), 195-226 (2012).
98. Seddighzadeh, A., Shetty, R. & Goldhaber, S. Z. Venous thromboembolism in patients with active cancer. Thromb. Haemost. 98, 656-661 (2007). (Pubitemid 47412893)
99. Department of Health. Using the Commissioning for Quality and Innovation (CQUIN) payment framework -Guidance on national goals for 2011/12 [online], http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/@ps/ documents/digitalasset/dh-123009.pdf (2010).
100. Department of Health. VTE risk assessment data collection; Q3 2011-2012 Key Points [online], http://transparency.dh.gov.uk/files/2012/03/VTE-Risk- Assessment-Q3-2011-12-Commentary-v1.pdf (2012).
101. Park, K., Oh, S. Y. & Kim, W. S. Randomised phase III trial of very low dose warfarin to prevent catheter-Associated thrombosis [abstract]. Proc. Am. Soc. Clin. Oncol. a2330 (1999).
102. Couban, S. et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-Associated thrombosis in patients with cancer. J. Clin. Oncol. 23, 4063-4069 (2005). (Pubitemid 46211311)
103. Bern, M. M. et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann. Intern. Med. 112, 423-428 (1990). (Pubitemid 20098523)
104. Heaton, D. C., Han, D. Y. & Inder, A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern. Med. J. 32, 84-88 (2002).
105. Young, A. M. et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): An open-label randomised trial. Lancet 373, 567-574 (2009).
106. Akl, E. A. et al. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD006468. http://onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD006468.pub4/full.
107. Hettiarachchi, R. J., Prins, M. H., Lensing, A. W. & Buller, H. R. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr. Opin. Pulm. Med. 4, 220-225 (1998). (Pubitemid 128354973)
108. Lee, A. Y. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146-153 (2003). (Pubitemid 36818784)
109. Deitcher, S. R. et al. Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin. Appl. Thromb. Hemost. 12, 389-396 (2006). (Pubitemid 44359237)
110. Meyer, G. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch. Intern. Med. 162, 1729-1735 (2002).
111. Hull, R. D. et al. Long-Term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am. J. Med. 119, 1062-1072 (2006). (Pubitemid 44826932)
112. Akl, E. A. et al. Anticoagulation for the long-Term treatment of venous thromboembolism in patients with cancer. Cochrane Database Systematic Reviews, Issue 15. Art. No.: CD006650. http://onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD006650.pub3/full.
113. Lee, A. Y. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 23, 2123-2129 (2005). (Pubitemid 46218703)
114. Sørensen, H. T., Mellemkjaer, L., Steffensen, F. H., Olsen, J. H. & Nielsen, G. L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N. Engl. J. Med. 338, 1169-1173 (1998). (Pubitemid 28180744)
115. Sørensen, H. T., Mellemkjaer, L., Olsen, J. H. & Baron, J. A. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846-1850 (2000). (Pubitemid 32104130)
116. Schulman, S. & Lindmarker, P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N. Engl. J. Med. 342, 1953-1958 (2000). (Pubitemid 30419090)
117. Young, A. Thromboprophylaxis in cancer patients with central venous catheters. Thesis, University of Birmingham (2010).
118. Zacharski, L. R. et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53, 2046-2052 (1984). (Pubitemid 14101772)
119. Chahinian, A. P. et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J. Clin. Oncol. 7, 993-1002 (1989). (Pubitemid 19196521)
120. Maurer, L. H. et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study. J. Clin. Oncol. 15, 3378-3387 (1997). (Pubitemid 27485858)
121. Altinbas, M. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2, 1266-1271 (2004). (Pubitemid 40186120)
122. Kakkar, A. K. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22, 1944-1948 (2004). (Pubitemid 41095187)
123. Klerk, C. P. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 23, 2130-2135 (2005). (Pubitemid 46218704)
124. Sideras, K. et al. Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial. Mayo Clin. Proc. 81, 758-767 (2006). (Pubitemid 43839491)
125. Akl, E. A. & Schünemann, H. J. Routine heparin for patients with cancer? One answer, more questions. N. Engl. J. Med. 366, 661-662 (2012).
126. Deftereos, S. et al. Prevention and treatment of venous thromboembolism and pulmonary embolism: The role of novel oral anticoagulants. Curr. Clin. Pharmacol. http://dx.doi.org/10.2174/1574212225641248847.
127. Levine, M. N. et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J. Thromb. Haemost. 10, 807-814 (2012).
128. Bauersachs, R. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499-510 (2010).
129. Büller, H. R. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287-1297 (2012).
130. Cohen, A. T. et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J. Thromb. Thrombol. 31, 407-416 (2011).
131. Guyatt, G. H. et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (Suppl. 2), 7-47 (2012).
132. Mandala, M. et al. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann. Oncol. 20 (Suppl. 4), 182-184 (2009).
133. Joffe, H. V., Kucher, N., Tapson, V. F. & Goldhaber, S. Z. Upper-extremity deep vein thrombosis: A prospective registry of 592 patients. Circulation 110, 1605-1611 (2004). (Pubitemid 39297983)
134. Kakkar, A. K., Levine, M., Pinedo, H. M., Wolff, R. & Wong, J. Venous thrombosis in cancer patients: Insights from the FRONTLINE survey. Oncologist 8, 381-388 (2003). (Pubitemid 36929723)
135. Department of Health. The Operating Framework: For the NHS in England 2012/13 [online], http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/ documents/digitalasset/dh-131428.pdf (2011).
136. NHS Litigation Authority. NHS Risk Management Standards 2012/13 [online], http://www.nhsla.com/NR/rdonlyres/6CBDEB8A-9F39-4A44-B04C-2865FD89C683/0/ NHSLARiskManagementStandards201213.pdf (2012).
137. Department of Health. Risk Assessment for Venous Thromboembolism (VTE) [online], http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/ @ps/documents/digitalasset/dh-113355.pdf (2010).
138. Khorana, A. A. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J. Thromb. Haemost. 6, 1983-1985 (2008).
139. Tesselaar, M. E. et al. Microparticle-Associated tissue factor activity: A link between cancer and thrombosis? J. Thromb. Haemost. 5, 520-527 (2007). (Pubitemid 46680685)
140. Uno, K. et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br. J. Cancer. 96, 290-295 (2007). (Pubitemid 46164734)
141. Tesselaar, M. E., Romijn, F. P., van der Linden, I. K., Bertina, R. M. & Osanto, S. Microparticle-Associated tissue factor activity in cancer patients with and without thrombosis. J. Thromb. Haemost. 7, 1421-1423 (2009).
142. Khorana, A. A. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 13, 2870-2875 (2007). (Pubitemid 46849560)
143. Ay, C. et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J. Clin. Oncol. 27, 4124-4129 (2009).
144. Ay, C. et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112, 2703-2708 (2008).
145. Kröger, K. et al. Risk factors for venous thromboembolic events in cancer patients. Ann. Oncol. 17, 297-303 (2006). (Pubitemid 43160121)
146. Chirinos, J. A. et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J. Am. Coll. Cardiol. 45, 1467-1471 (2005). (Pubitemid 40615620)
147. Dawar, J. R., Rose, P. E., Chant, I. D. & Gordge, M. Are circulating endothelial cells increased in patients with venous thromboembolism and are levels greater in patients with underlying malignancy and venous thromboembolism? Br. J. Haematol. 153 (Suppl. 1), 7 (2011).
148. Falanga, A. et al. Cancer procoagulant and tissue factor are differently modulated by all-Trans-retinoic acid in acute promyelocytic leukemia cells. Blood 92, 143-151 (1998). (Pubitemid 28303186)